Literature DB >> 4572168

Length of treatment with anxiolytic sedatives and response to their sudden withdrawal.

L Covi, R S Lipman, J H Pattison, L R Derogatis, E H Uhlenhuth.   

Abstract

Mesh:

Substances:

Year:  1973        PMID: 4572168     DOI: 10.1111/j.1600-0447.1973.tb04398.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


× No keyword cloud information.
  16 in total

Review 1.  Benzodiazepines. Depressants or antidepressants?

Authors:  J W Tiller; I Schweitzer
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 2.  Use of antianxiety agents in anxious outpatients.

Authors:  K Rickels
Journal:  Psychopharmacology (Berl)       Date:  1978-06-15       Impact factor: 4.530

3.  Psychopharmacoepidemiology in Iceland: effects of regulations and new medications.

Authors:  T Helgason; J K Björnsson; T Zoëga; H S Thorsteinsson; H Tómasson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

4.  Are benzodiazepines overused and abused?

Authors:  K Rickels
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

5.  Lorazepam withdrawal seizures.

Authors:  J G Howe
Journal:  Br Med J       Date:  1980-05-10

6.  Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate.

Authors:  J S Duncan; S D Shorvon; M R Trimble
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

7.  Abuse potential of benzodiazepines.

Authors:  D A Ciraulo
Journal:  Bull N Y Acad Med       Date:  1985-10

8.  Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome.

Authors:  E Schweizer; W G Case; F Garcia-Espana; D J Greenblatt; K Rickels
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

9.  Long-Term Use of Benzodiazepines: Implications and guidelines.

Authors:  N L Potts; K R Krishnan
Journal:  Can Fam Physician       Date:  1992-01       Impact factor: 3.275

Review 10.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.